Low Dose Naltrexone

Low-dose naltrexone (LDN) is a low-dose formulation (typically 1-5 mg) of the opioid antagonist naltrexone, used off-label to relieve chronic pain from conditions like fibromyalgia and multiple sclerosis by boosting endorphins, modulating immunity, and reducing inflammation.

Brief glance

The primary outcome is Immune Support, but it's also used for Recovery & Repair. This compound is considered a Small Molecule. It is also known as LDN, Naltrexone. It may be compounded in 503A pharmacies where allowed. It is not listed under a DEA schedule.

Overview

Low-dose naltrexone (LDN) is a medication using doses roughly one-tenth of standard opioid addiction treatment, typically around 4.5 mg daily, that works by temporarily blocking opioid receptors to trigger increased endorphin production and reduce inflammation. It has been studied for treating chronic pain conditions including fibromyalgia, multiple sclerosis, and Crohn's disease, with research suggesting it is safe and generally well-tolerated with minimal side effects. Unlike traditional painkillers, LDN is non-addictive and is considered investigational for chronic pain and autoimmune conditions, though it remains an off-label treatment option due to limited large-scale clinical trials.

Low-dose naltrexone (LDN) is naltrexone administered at substantially reduced doses, typically 1 to 5 mg daily, compared to the standard 50 mg used for opioid addiction and alcohol dependence treatment. Originally pioneered by Dr. Bernard Bihari in the 1980s for AIDS, LDN works via transient opioid receptor blockade that boosts endorphin production, modulates Toll-like receptor 4 to curb glial inflammation, and regulates immune function. It is explored off-label for chronic conditions like fibromyalgia, multiple sclerosis, Crohn's disease, complex regional pain syndrome, and autoimmune disorders, often showing pain relief, reduced inflammation, and improved quality of life with minimal side effects. Though not FDA-approved for these uses and lacking large-scale trials, LDN is generally well-tolerated, non-addictive, and compounded by pharmacists for evening dosing.

Benefits

Low-dose naltrexone reduces symptom severity, including pain and inflammation, in fibromyalgia, Crohn's disease, multiple sclerosis, and complex regional pain syndrome through anti-inflammatory effects on glial cells and modulation of cytokines.¹,²,³ In Crohn's disease trials, it improved symptoms in 88% of patients and induced remission in about 33% within 12 weeks, while also enhancing quality of life in multiple sclerosis.¹,³,⁴ Additional benefits include pain relief, improved fatigue, sleep, mood, and cognitive function in chronic pain and autoimmune conditions, with a favorable safety profile and low risk of adverse effects like headache or gastrointestinal upset.¹,²,⁵

Side effects

Low-dose naltrexone (LDN) is generally well-tolerated with mostly mild and temporary side effects such as vivid dreams, headaches, dizziness, nausea, sleep disturbances, fatigue, gastrointestinal issues like diarrhea or stomach pain, anxiety, and muscle or joint pain.⁵,⁶,⁷,⁸,⁹,¹⁰,² These symptoms often resolve as the body adjusts, and starting at a low dose like 0.5 mg with gradual titration can minimize them, particularly in sensitive conditions like fibromyalgia.⁸,¹¹ Rare serious side effects may include depression, liver problems, severe allergic reactions, blurred vision, hallucinations, confusion, or opioid withdrawal/overdose if opioids are used concurrently or recently.⁶,⁷,¹²,¹³ Key safety considerations involve avoiding opioids for at least 10 days before starting LDN to prevent precipitated withdrawal, monitoring liver function especially at higher doses, and consulting a healthcare provider for persistent or worsening symptoms, with dose timing adjustments (e.g., morning for sleep issues) often helpful.⁶,⁷,¹⁰ Long-term use at low doses (1-5 mg) shows uncommon severe effects compared to standard higher doses.⁵,⁶,⁹

Mechanisms of action

Low-dose naltrexone (LDN), typically administered at 1-5 mg daily, primarily acts through transient blockade of opioid receptors, which upregulates endogenous opioid production including endorphins and met-enkephalins, enhancing opioid signaling and immune modulation.¹⁴,¹⁵,¹⁶ This "rebound" effect temporarily interrupts continuous receptor occupancy, leading to increased expression of μ-, δ-, and ζ-opioid receptors.¹⁴ Simultaneously, LDN binds to Toll-like receptor 4 (TLR4) on microglia and immune cells as an antagonist, disrupting downstream signaling pathways like TRIF and reducing pro-inflammatory cytokines such as TNF-α, IL-1, interferon-β, and nitric oxide.¹⁴,¹⁶,¹⁷ These dual mechanisms—opioid upregulation and glial modulation—suppress neuroinflammation and immune overactivity, contributing to its therapeutic effects in conditions like chronic pain and autoimmunity.¹,³,¹⁴